Image of Heart shaped leaves on a plant for In Memory

Heart failure with preserved ejection fraction

By Sean Zheng

Key messages

  • Heart failure with preserved ejection fraction (HFPEF) is a common cause of hospitalisation, impaired quality of life, restricted functional capacity, and mortality. There are currently no specific treatments for HFPEF with proven efficacy.
  • PARAGON-HF (sacubitril-valsartan) demonstrated statistically non-significant improvements in heart failure outcomes in HFPEF, most notably signs of greater efficacy in those participants with lower left ventricular ejection fractions.
  • Ongoing studies (DELIVER and EMPEROR-Preserved) will evaluate the effects of SGLT-2 inhibitors, a class of agent with striking efficacy in heart failure with reduced ejection fraction, in HFPEF.

Read the full BCS editorial